Previous 10 | Next 10 |
MannKind (NASDAQ:MNKD) saw its Q3 2021 net loss narrow 61% to $4.4M (-$0.02 cents per share) as revenue increased 45% year over year. Shares are up ~3.8% in after-hours trading. The company benefited from $9.8M in Afrezza inhaled insulin sales in the quarter. That was 34% higher tha...
United Therapeutics Corporation (UTHR) Q3 2021 Earnings Conference Call November 03, 2021, 09:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO Leigh Peterson - SVP, Product Development James Edgemond - CFO an...
Image source: The Motley Fool. United Therapeutics Corporation (NASDAQ: UTHR) Q3 2021 Earnings Call Nov 3, 2021 , 9:00 a.m. ET Operator Continue reading For further details see: United Therapeutics Corporation (UTHR) Q3 2021 Earnings Call...
United Therapeutics (NASDAQ:UTHR): Q3 Non-GAAP EPS of $4.16 beats by $0.07; GAAP EPS of $3.42 misses by $0.16. Revenue of $444.7M (+17.0% Y/Y) beats by $23.25M. Press Release For further details see: United Therapeutics EPS beats by $0.07, beats on revenue
United Therapeutics Corporation Reports Third Quarter 2021 Financial Results PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Nov. 3, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a pur...
United Therapeutics (NASDAQ:UTHR) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is $4.09 (+5.4% Y/Y) and the consensus Revenue Estimate is $421.45M (+10.9% Y/Y). Over the last 2 years, UTHR has beaten EPS estimates 75% ...
United Therapeutics Corporation To Present At The Credit Suisse 30th Annual Healthcare Conference PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Nov. 1, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today tha...
Liquidia is a biotech focused on the Pulmonary Arterial Hypertension space. It jointly markets a generic version of Treprostinil with Sandoz - part of Novartis, and has an inhaled form which could be approved by the FDA next month. Competition from market incumbent United Therapeu...
Amendment expands program from a singular focus on the bioprinting of human lung scaffolds to the development and demonstration of two additional human organs Amendment will become effective upon closing of 3D Systems’ acquisition of Volumetric Biotechnologies, Inc., which wa...
United Therapeutics Corporation To Report Third Quarter 2021 Financial Results Before The Market Opens On Wednesday, November 3, 2021 PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 27, 2021 /PRNewswire/ -- United Therapeutics Corp...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...